QCI Interpret for Oncology

Comprehensive Molecular Tumor Analysis with Alacris Theranostics

276 views
March 09, 2023
Precision oncology approaches have made great strides harnessing individual tumor mutation profiles to guide targeted therapy choices. However, deeper molecular insights are needed to improve personalized treatment decisions. Integrating gene expression analysis in personalized oncology provides an additional level of insight. These analyses include evaluating expressed mutations and drug targets, novel gene fusions, clinically relevant signatures, and the tumor immune microenvironment (TME).

Alacris Theranostics developed the Comprehensive Molecular Tumor Analysis (CMTA), a NGS-based tumor diagnostic test. The test integrates whole exome and transcriptomic sequencing (WES and RNAseq). The test deploys as an end-to-end accredited diagnostic platform from tumor sample uptake (FFPE or frozen) to personalized clinical interpretation reports.  CMTA is a tumor-agnostic test that displays a unique molecular view of each sample. CMTA is a useful approach for refractory cancers with complex patterns or tumors of unknown origin.

In this webinar, viewers will:

Learn about the strategy implemented in Alacris’ bioinformatics pipeline to identify cancer-relevant somatic events
Learn how Alacris uses QCI Interpret for Oncology to annotate variants and identify potential therapies
Be eligible for a complimentary QCI Interpret demo and sample report

Related videos

QCI Interpret for Oncology

QCI Interpret One: Oncology variant interpretation just got more precise

1,017 views June 12, 2020

Competing to offer a comprehensive genomic profiling service for solid or...

QCI Interpret for Oncology

Precision medicine for any cancer assay on any platform

1,013 views May 29, 2019

For NGS cancer testing, keeping pace with new discoveries is a serious...

QCI Interpret for Oncology

Managing multiple biomarker therapeutic development

402 views September 12, 2019

For the past two decades, the paradigm in the field has been “one biomarker,...

QCI Interpret for Oncology

FASTQ to final report: Ultra-fast workflow for CGP

371 views July 21, 2022

As our molecular knowledge of cancer continually evolves, a new era in cancer...